Trial Profile
An Open Label, Parallel Group, Randomized Phase I Study of Biological Activity, Safety, Tolerability, and Clinical Activity of Different Dose Levels of EMD 640 744 in Montanide ISA 51 VG Administered in Subjects With Advanced Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 25 Sep 2021
Price :
$35
*
At a glance
- Drugs Maveropepimut-S (Primary) ; Montanide ISA-51
- Indications Solid tumours
- Focus Pharmacodynamics
- Sponsors Merck KGaA
- 20 Mar 2018 According to Immunovaccine media release, Preliminary clinical results are expected around mid-year and Topline clinical results are expected around the end of the year or beginning of 2019
- 03 Oct 2011 Actual end date Sep 2011 added as reported by ClinicalTrials.gov.
- 03 Oct 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.